Description
Acestine (N-Acetylcysteine) 600 mg
Acestine 600 mg contains N-acetylcysteine (acetylcysteine, NAC), a medicine used as a mucolytic agent. It is primarily recognised for helping reduce the thickness of respiratory mucus so it can be cleared more easily from the airways. It also has antioxidant properties.
Active Ingredient and Medicine Class
The verified active ingredient is N-acetylcysteine. It belongs to the mucolytic class of medicines and is also described as an antioxidant. Regulatory and prescribing information for acetylcysteine products identifies it as a drug used for respiratory mucus disorders, while broader medical use also includes acetaminophen overdose in other formulations and settings.
Established Medical Uses
Official prescribing information for acetylcysteine as a mucolytic describes its use as adjuvant therapy for abnormal, viscid, or inspissated mucous secretions in chronic bronchopulmonary conditions, including chronic bronchitis and related disorders. Clinical reviews and meta-analyses have also evaluated oral NAC in chronic bronchitis and COPD, with evidence suggesting possible benefit in reducing exacerbations in some patients, although results across studies are mixed.
How It Works
N-acetylcysteine helps break down mucus by reducing the chemical bonds that make secretions thick and sticky. This can lower mucus viscosity and support airway clearance. It is also an antioxidant, and published reviews describe additional biologic effects related to oxidative stress and inflammation in chronic respiratory disease.
Important Safety Information
Acetylcysteine is contraindicated in people with known sensitivity to the medicine. Prescribing information warns that bronchospasm can occur, and treatment should be stopped if it progresses. Respiratory irritation has also been reported. In children, especially very young patients, oral mucolytics have been associated with paradoxical respiratory worsening in some reports.
Clinically important interactions depend on the formulation and indication, but the most relevant established safety concern in the literature is the potential for hypersensitivity-like reactions and respiratory effects. Oral acetylcysteine may also aggravate vomiting in some settings.
Possible Side Effects
Reported adverse effects include nausea, vomiting, gastrointestinal discomfort, flushing, rash, pruritus, chest tightness, dyspnea, wheeze, and bronchospasm. Serious reactions are uncommon but can include marked hypersensitivity-type responses and breathing difficulty.
Scientific Evidence
Systematic reviews and meta-analyses of oral NAC in chronic bronchitis and COPD suggest it may reduce exacerbations and improve symptoms in some patients, while other analyses note that more recent studies show smaller or less consistent benefit than earlier trials. Overall, the evidence supports NAC as a mucolytic option with potential adjunctive value in selected chronic respiratory conditions, rather than a universal treatment.
Medical Information Notice
This page is an educational summary based on sources available at the time of review. It does not replace the official patient leaflet, product label, or assessment by a qualified healthcare professional.
Medical Sources
- U.S. Food and Drug Administration / DailyMed — Acetylcysteine Solution, USP
- U.S. Food and Drug Administration — Mucomyst (acetylcysteine) Approval Package / Prescribing Information
- Stey C, Steurer J, Bachmann S, Medici TC, Tramer MR. “The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review.” PubMed (2000). PubMed article